Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
NCT02419287Phase 2Completed
- Sponsor
- University of Milano-Bicocca
- Start
- Apr 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in anaplastic large cell lymphoma (ALCL), sponsored by University of Milano-Bicocca. Started Apr 2015; status: completed.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT02419287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419287.